AstraZeneca

Final overall survival results from TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) did not achieve statistical significance in HR-positive, HER2-low or negative breast cancer patients, despite positive progression-free survival results. Safety profile remained consistent with no new concerns. Subsequent treatment options likely affected survival results.

DelveInsight's 'HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024' covers 5+ companies and 5+ pipeline drugs, including clinical and nonclinical profiles, therapeutic assessments by product type, stage, route of administration, and molecule type, highlighting inactive products. Key companies include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, and Spectrum Pharmaceuticals Inc., with promising therapies like Trastuzumab deruxtecan and Poziotinib.

FDA approves first self-administered flu vaccine, FluMist, by AstraZeneca, available for next respiratory virus season. This nasal spray, already used since 2003, offers a needle-free option for ages 2-49, potentially increasing convenience and accessibility.

EMA recommends Novo Nordisk's Wegovy for heart failure in obese individuals, expanding its use beyond weight loss. FDA approves Zevra Therapeutics' drug for a rare genetic disorder and AstraZeneca's nasal spray flu vaccine. FTC sues top U.S. pharmacy benefit managers over insulin price inflation. UNICEF stresses stigma combat in Burundi's mpox outbreak.

Recent health news highlights include: EMA endorses Novo Nordisk's Wegovy for heart failure in obesity, FDA approves Zevra Therapeutics' treatment for a rare genetic disorder, FTC sues pharmacy benefit managers over insulin pricing, U.N. official suggests mpox in Burundi can be tackled within weeks, Sanofi's tolebrutinib shows promise in MS, Missouri healthcare worker contracts bird flu, FDA approves AstraZeneca's nasal spray flu vaccine, early studies show potential in rejuvenating older eggs for IVF and preventing newborn jaundice, U.S. appeals court revives lawsuit against Medicare drug price negotiation, and FDA approves Sanofi's Sarclisa for multiple myeloma treatment.

FDA approves first self-administered flu vaccine, FluMist, a nasal spray by MedImmune/AstraZeneca. Available for ages 2+, it offers convenience, flexibility, and accessibility, potentially boosting declining flu vaccination rates.

Warren Kotler, a 61-year-old man with Stage 4 metastatic breast cancer, has outlived his prognosis by receiving various treatments. His oncologist suggested a new drug, capivasertib (Truqap), which could delay cancer progression but is currently approved only for women in Canada due to insufficient male participation in clinical trials. Kotler's medical team seeks compassionate use of the drug, but AstraZeneca denies coverage, citing Health Canada's approval restrictions. Despite the drug's potential benefits and similar disease biology in men and women, regulatory bodies face challenges due to the rarity of male breast cancer cases.

FDA approves AstraZeneca's FluMist, the first self-administered flu vaccine spray, offering greater convenience and accessibility.

The FDA approved a self-administered flu vaccine, FluMist by AstraZeneca, which will be available for home use next respiratory season, aiming to improve convenience and accessibility.

FDA approves first self-administered nasal spray flu vaccine, FluMist by AstraZeneca, available online for ages 2-49, aiming to boost vaccination rates.